Uvax Bio develops and commercializes prophylactic vaccines for challenging infectious diseases using proprietary 1c-SA p NP® platform technology. The company focuses on combining rational antigen design and protein engineering to create virus-like particle vaccines. This approach aims to deliver vaccine solutions for unmet public health needs against infectious disease threats.
Funding
$21M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many infectious diseases, such as HIV-1, pose significant public health challenges due to their complex biology and the difficulty in eliciting broadly neutralizing antibody responses through traditional vaccine approaches. Developing effective prophylactic vaccines for these diseases requires innovative antigen design and delivery strategies.
Solution
Uvax Bio is developing a new class of prophylactic vaccines for challenging infectious diseases based on its proprietary 1c-SA_p_NP® platform technology. This platform uses rational antigen design and protein engineering to create virus-like particle vaccines that closely mimic the native structure of pathogens. By presenting antigens in a highly organized and repetitive manner, the 1c-SA_p_NP® platform aims to stimulate a robust and durable immune response, including the production of broadly neutralizing antibodies. The company's lead vaccine candidates target HIV-1 and are designed to address critical unmet needs in global public health.
Target Audience
The primary target audience includes individuals at risk of infection from challenging infectious diseases, as well as public health organizations and government agencies seeking effective preventative measures.
Features
- 1c-SA_p_NP® platform technology for creating virus-like particle vaccines
- Rational antigen design and protein engineering to optimize immunogenicity
- Vaccine constructs designed to elicit broadly neutralizing antibody responses
- High-yield research cell bank (RCB) development for scalable manufacturing
- Preclinical data demonstrating promising immune responses
- HIV-1 vaccine candidates in preparation for Phase 1 clinical trials